DDInter1266 DDInter1297
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) upregulates {v} (Gene) VAV3
VAV3 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lepirudin
Lepirudin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Flurbiprofen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) upregulates VAV3 (Gene) and VAV3 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) resembles Nabumetone (Compound) and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Naproxen (Compound) resembles Nabumetone (Compound) and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib